Ipsen S.A. (FRA:I7G)

Germany flag Germany · Delayed Price · Currency is EUR
122.20
-0.20 (-0.16%)
At close: Dec 5, 2025
12.83%
Market Cap 10.01B
Revenue (ttm) 3.76B
Net Income (ttm) 447.90M
Shares Out n/a
EPS (ttm) 5.37
PE Ratio 22.35
Forward PE 10.62
Dividend 1.40 (1.14%)
Ex-Dividend Date Jun 4, 2025
Volume n/a
Average Volume 30
Open 122.20
Previous Close 122.40
Day's Range 122.20 - 122.20
52-Week Range 90.20 - 130.80
Beta n/a
RSI 45.98
Earnings Date Feb 12, 2026

About Ipsen

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical t... [Read more]

Industry Pharmaceutical Preparations
Founded 1929
Employees 5,358
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol I7G
Full Company Profile

Financial Performance

In 2024, Ipsen's revenue was 3.57 billion, an increase of 8.11% compared to the previous year's 3.31 billion. Earnings were 345.90 million, a decrease of -46.32%.

Financial Statements

News

There is no news available yet.